The document discusses five main areas of research at Biogen: neurology, immunology, oncology, hemophilia, and cardiopulmonary diseases. It also lists drugs in various phases of development and FDA-approved drugs. Work in quality assurance ensures proper analysis of exceptions and product data, technical expertise, and evaluation of facilities and processes used like various types of chromatography and electrophoresis.
Upoznajte prvo i jedino udruženje u Srbiji koje se poslednje 4 godine aktivno bavi poručavanjem uticaja nejonizujućeg zračenja na zdravlje ljudi i životnu sredinu. sarađujemo sa WHO, IRPA, ICNIRP, ITU, EBEA, BfS INIS, BION i drugim svetskim organizacijama i institucijama koje su lideri u ovoj oblasti .
Upoznajte prvo i jedino udruženje u Srbiji koje se poslednje 4 godine aktivno bavi poručavanjem uticaja nejonizujućeg zračenja na zdravlje ljudi i životnu sredinu. sarađujemo sa WHO, IRPA, ICNIRP, ITU, EBEA, BfS INIS, BION i drugim svetskim organizacijama i institucijama koje su lideri u ovoj oblasti .
William F. C. Rigby, MD, and Gregg J. Silverman, MD, prepared useful Practice Aids pertaining to rheumatoid arthritis for this CME activity titled "Improving Outcomes for Patients With Refractory Rheumatoid Arthritis: The Role of JAK Inhibitors." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2MLFVtI. CME credit will be available until October 8, 2019.
INTEREST: Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients...Intensive Care Society
Geoff is a consultant in intensive care medicine (UCLH) and Reader in Intensive Care at UCL. He is the Hon secretary of the European Society of Intensive Care Medicine (ESICM) and is a member of the Critical Care Committee for the Royal College of Physicians and the research committee for the Intensive Care Society (ICS).
Geoff’s research interests are ARDS infection and the resolution of inflammation, having studied macrophage clearance then fibrosis in ARDS for his PhD and MRC clinician scientist fellowships respectively. Geoff has published widely on pathophysiology and clinical trials in acute lung injury and on MRSA. He is currently leading on the FP7 trial.
Paul Frohna is Chief Medical Officer of Bioniz Therapeutics where he oversees clinical and regulatory strategy and operations for the company’s platform of multi-cytokine inhibitors that are in development for alopecia areata, cutaneous T cell lymphoma, and a variety of other autoimmune diseases
Constance Benson, MD
Professor of Medicine and Director of the UC San Diego
AntiViral Research Center
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
William F. C. Rigby, MD, and Gregg J. Silverman, MD, prepared useful Practice Aids pertaining to rheumatoid arthritis for this CME activity titled "Improving Outcomes for Patients With Refractory Rheumatoid Arthritis: The Role of JAK Inhibitors." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2MLFVtI. CME credit will be available until October 8, 2019.
INTEREST: Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients...Intensive Care Society
Geoff is a consultant in intensive care medicine (UCLH) and Reader in Intensive Care at UCL. He is the Hon secretary of the European Society of Intensive Care Medicine (ESICM) and is a member of the Critical Care Committee for the Royal College of Physicians and the research committee for the Intensive Care Society (ICS).
Geoff’s research interests are ARDS infection and the resolution of inflammation, having studied macrophage clearance then fibrosis in ARDS for his PhD and MRC clinician scientist fellowships respectively. Geoff has published widely on pathophysiology and clinical trials in acute lung injury and on MRSA. He is currently leading on the FP7 trial.
Paul Frohna is Chief Medical Officer of Bioniz Therapeutics where he oversees clinical and regulatory strategy and operations for the company’s platform of multi-cytokine inhibitors that are in development for alopecia areata, cutaneous T cell lymphoma, and a variety of other autoimmune diseases
Constance Benson, MD
Professor of Medicine and Director of the UC San Diego
AntiViral Research Center
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Presentation1
1. FIVE MAIN AREAS OF RESEARCH
• Neurology: MS, Parkinson’s disease
AVONEX® and TYSABRI®
Silence the inflammation
• Immunology: Rheumatoid Arthritis
RITUXAN® ; IgG1kappa Ab – against CD20 Ag
• Oncology: Non hodgkins lymphoma
RITUXAN® ; tergets CD20 Ag
• Hemophillia: rFIXFc
Fc fused blood clotting factor
• Cardiopulmonary: ADENTRI® (Phase 2), Lixivaptan (phase 3)
A1 adenosine receptor antagonist.
address hyponatremia and renal failure.
2. PHASES DRUGS
FDA APPROVED DRUGS
PHASE 1 ANTI-LINGO, NEBULASTIN, CD40L,
ANTI-TWEAK, BIIB037 (HUMAN
ANTI-AMYLOID B MAB)
PHASE 2 OCRELIZUMAB (HUMANIZED
ANTI-CD20 MAB).
PHASE 3 PEG IFN (PEGYLATED
INTERFERON BETA-1A), BG-12
(DIMETHYLFUMARATE),
DACLIZUMAB, LONG LASTING r
FACTOR IX, LONG LASING r
FACTOR VIII, GA101 (HUMANIZED
ANTI-CD20 MAB),
DEXPRAMIPEXOLE.
PHASE 4 -------
FILLING -------
3. WORK DONE IN QUALITY ASSURANCE
DEVELOPMENT, MAINTENANCE AND MANAGEMENT OF QUALITY SYSTEMS
ENSURE THAT EXCEPTIONS ARE ANALYZED FOR PREVENTIVE ACTIONS AND
PRODUCT IMPACT.
DEVELOP AND MAINTAIN DATA ANALYSIS AND TRENDING SYSTEMS FOR PRODUCT
SPECIFIC DATA GENERATED AT THE FACILITY.
PROVIDE TECHNICAL EXPERTISE FOR PRODUCT QUALITY DECISIONS.
MAINTAIN PRODUCT DISPOSITION PROCEDURES.
EVALUATION OF FACILITY, PROCEDURES, EQUIPMENT, PERSONNEL AND
PROCESSES.
PROCESSES USED
MASS SPECTROSCOPY: ESI TOF MS, MALDI MS,LC UV MS.
CHROMATOGRAPHY: HIC, RPLC, SEC, ION EXCHANGE CHROMATOGRAPHY,
SDS PAGE
cIEF
